

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:ssspta1653hxp

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

\* \* \* \* \* \* \* \* \* \* \* \* Welcome to STN International \* \* \* \* \* \* \* \* \* \*

NEWS 1 Web Page for STN Seminar Schedule - N. America  
NEWS 2 JAN 02 STN pricing information for 2008 now available  
NEWS 3 JAN 16 CAS patent coverage enhanced to include exemplified prophetic substances  
NEWS 4 JAN 28 USPATFULL, USPAT2, and USPATOLD enhanced with new custom IPC display formats  
NEWS 5 JAN 28 MARPAT searching enhanced  
NEWS 6 JAN 28 USGENE now provides USPTO sequence data within 3 days of publication  
NEWS 7 JAN 28 TOXCENTER enhanced with reloaded MEDLINE segment  
NEWS 8 JAN 28 MEDLINE and LMEDLINE reloaded with enhancements  
NEWS 9 FEB 08 STN Express, Version 8.3, now available  
NEWS 10 FEB 20 PCI now available as a replacement to DPCI  
NEWS 11 FEB 25 IFIREF reloaded with enhancements  
NEWS 12 FEB 25 IMSPRODUCT reloaded with enhancements  
NEWS 13 FEB 29 WPINDEX/WPIDS/WPIX enhanced with ECLA and current U.S. National Patent Classification  
NEWS 14 MAR 31 IFICDB, IFIPAT, and IFIUDB enhanced with new custom IPC display formats  
NEWS 15 MAR 31 CAS REGISTRY enhanced with additional experimental spectra  
NEWS 16 MAR 31 CA/Caplus and CASREACT patent number format for U.S. applications updated  
NEWS 17 MAR 31 LPCI now available as a replacement to LDPCI  
NEWS 18 MAR 31 EMBASE, EMBAL, and LEMBASE reloaded with enhancements  
NEWS 19 APR 04 STN AnaVist, Version 1, to be discontinued  
NEWS 20 APR 15 WPIDS, WPINDEX, and WPIX enhanced with new predefined hit display formats  
NEWS 21 APR 28 EMBASE Controlled Term thesaurus enhanced  
NEWS 22 APR 28 IMSRESEARCH reloaded with enhancements

NEWS EXPRESS FEBRUARY 08 CURRENT WINDOWS VERSION IS V8.3,  
AND CURRENT DISCOVER FILE IS DATED 20 FEBRUARY 2008

NEWS HOURS STN Operating Hours Plus Help Desk Availability  
NEWS LOGIN Welcome Banner and News Items  
NEWS IPC8 For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may

result in loss of user privileges and other penalties.

FILE 'HOME' ENTERED AT 16:04:58 ON 16 MAY 2008

=> file medline  
COST IN U.S. DOLLARS

	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'MERLINE' ENTERED AT 16:05:18 ON 16 MAY 2008

FILE LAST UPDATED: 15 May 2008 (20080515/UP). FILE COVERS 1949 TO DATE.

MEDLINE has been updated with the National Library of Medicine's revised 2008 MeSH terms. See [HELP](#) [LOAD](#) for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

See HELP RANGE before carrying out any RANGE search.

=> s (three hybrid system and methasone-FK506)

1321800 THREE  
66747 HYBRID  
1392301 SYSTEM  
    102 THREE HYBRID SYSTEM  
                (THREE(W)HYBRID(W)SYSTEM)  
    133 METHASONE  
38300 FFK506  
    0 METHASONE-FK506  
                (METHASONE(W)FK506)  
    0 (THREE HYBRID SYSTEM AND ME

L1 0 (THREE HYBRID SYSTEM AND METHASONE-FK506)

=> s FK506

=> s 12 and (methotrexate)  
33516 METHOTREXATE  
L3 70 L2 AND (METHOTREXATE)

=> s 13 and ligand  
127155 LIGAND

=> d 14 + i abs ibib tot

L4 ANSWER 1 OF 2 MEDLINE on STN  
TI Immunopathogenesis of acute graft-versus-host disease: implications for novel preventive and therapeutic strategies.  
AB Acute graft-versus-host disease (GVHD) is a primary T-cell-mediated complication of allogeneic hematopoietic stem cell transplantation (HSCT), occurring when donor-derived T cells are stimulated by host antigen-presenting cells (APCs), enhanced by proinflammatory cytokines such as interleukin (IL)-1, IL-6, IL-8, and tumor necrosis factor (TNF)-alpha. Recent data indicate that besides differences in major histocompatibility and minor histocompatibility antigens, cytokine gene polymorphisms have a predictive value for the complication of GVHD. Patients with a high anti-inflammatory IL-10 production have been demonstrated to be protected from GVHD while patients with high TNF-alpha

serum levels were more at risk for GVHD. Pharmacological immunosuppression for GVHD prophylaxis and therapy, including unspecific approaches with corticosteroids or methotrexate (MTX), as well as more specific therapy with cyclosporin A (CsA), tacrolimus (FK506), sirolimus, mycophenolate mofetil (MMF), antithymocyte globulin (ATG), and monoclonal antibodies (MAbs) directed against CD3, CD25, CD52, cytotoxic T-lymphocyte antigen (CTLA)-4, CD40 ligand, or TNF-alpha, have been proven to be effective. Recent data on novel techniques to selectively deplete alloreactive T cells by removal, destruction, or anergy induction while preserving leukemia-specific T-cell clones suggest a clinical benefit from these approaches. Gene-modified T cells that can selectively be depleted and CD4(+)CD25(+) regulatory T cells are under investigation for their ability to modulate alloreactivity after HSCT. With a better understanding of the immunopathogenesis of acute GVHD and the technical improvement of recently described therapeutic approaches, such as removal of naive T cells, selection of Th2 cells, suicide gene transduced T cells, and adoptive transfer of regulatory T cells, the use of alloreactivity as a treatment modality may be expanded to nonhematological disease entities such as solid tumors or autoimmune disorders.

ACCESSION NUMBER: 2004478960 MEDLINE  
DOCUMENT NUMBER: PubMed ID: 15449032  
TITLE: Immunopathogenesis of acute graft-versus-host disease: implications for novel preventive and therapeutic strategies.  
AUTHOR: Zeisler Robert; Marks Reinhard; Bertz Hartmut; Finke Jurgen  
CORPORATE SOURCE: Department of Hematology and Oncology, Albert Ludwigs University Medical Center Freiburg, Hugstetterstr. 55, 79106 Freiburg, Germany.. zeisler@mm1.ukl.uni-freiburg.de  
SOURCE: Annals of hematology, (2004 Sep) Vol. 83, No. 9, pp. 551-65. Electronic Publication: 2004-06-15. Ref: 183  
Journal code: 9107334. ISSN: 0939-5555.  
PUB. COUNTRY: Germany; Germany, Federal Republic of  
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)  
General Review; (REVIEW)  
LANGUAGE: English  
FILE SEGMENT: Priority Journals  
ENTRY MONTH: 200410  
ENTRY DATE: Entered STN: 28 Sep 2004  
Last Updated on STN: 22 Oct 2004  
Entered Medline: 20 Oct 2004

L4 ANSWER 2 OF 2 MEDLINE on STN  
TI Correlation between ligand-receptor affinity and the transcription readout in a yeast three-hybrid system.  
AB The yeast two-hybrid assay has proven to be a powerful method to detect protein-protein interactions as well as to derive genome-wide protein interaction maps. More recently, three-hybrid assays have emerged as a means to detect both protein-RNA and protein-small molecule interactions. Despite the routine use of the two-hybrid assay and the potential of three-hybrid systems, there has been little quantitative characterization to understand how the strength of the protein interaction correlates with transcription activation. It is not known if the additional interaction in three-hybrid systems compromises the sensitivity of the system. Thus, here, we set out to determine the K(D) cutoff of a small molecule three-hybrid system and to determine if there is a correlation between the K(D) and the levels of transcription activation. A series of mutations to FK506-binding protein 12 (FKBP12) were designed to vary the affinity of this protein for the small molecule synthetic ligand for FK506-binding protein 12 (SLF). These FKBP12 variants were overexpressed and purified, and their K(D)'s for SLF were measured using a

fluorescence polarization assay. Then the levels of transcription activation in a Mtx-DHFR yeast three-hybrid system were determined for these variants using a lacZ reporter gene. The K(D) cutoff of the Mtx yeast three-hybrid system is found to be ca. 50 nM. Further, the levels of transcription activation correlate with the strength of the binding interaction, though the dynamic range is only 1 order of magnitude. These results establish that the three-hybrid assay has the requisite sensitivity for drug discovery. However, the small dynamic range highlights a limitation to equilibrium-based assays for discriminating interactions based on affinity.

ACCESSION NUMBER: 2004397997 MEDLINE  
DOCUMENT NUMBER: PubMed ID: 15301533  
TITLE: Correlation between ligand-receptor affinity and the transcription readout in a yeast three-hybrid system.  
AUTHOR: de Felipe Karim Suwan; Carter Brian T; Althoff Eric A; Cornish Virginia W  
CORPORATE SOURCE: Integrated Program in Cellular, Molecular, and Biophysical Studies, Columbia University, New York, New York 10027, USA.  
CONTRACT NUMBER: R01-GM62867 (United States NIGMS)  
SOURCE: Biochemistry, (2004 Aug 17) Vol. 43, No. 32, pp. 10353-63.  
Journal code: 0370623. ISSN: 0006-2960.  
PUB. COUNTRY: United States  
DOCUMENT TYPE: (COMPARATIVE STUDY)  
Journal; Article; (JOURNAL ARTICLE)  
(RESEARCH SUPPORT, NON-U.S. GOVT)  
(RESEARCH SUPPORT, U.S. GOVT, P.H.S.)  
LANGUAGE: English  
FILE SEGMENT: Priority Journals  
ENTRY MONTH: 200409  
ENTRY DATE: Entered STN: 11 Aug 2004  
Last Updated on STN: 15 Sep 2004  
Entered Medline: 14 Sep 2004

=> d his

(FILE 'HOME' ENTERED AT 16:04:58 ON 16 MAY 2008)

FILE 'MEDLINE' ENTERED AT 16:05:18 ON 16 MAY 2008  
0 S (THREE HYBRID SYSTEM AND METHASONE-FK506)  
L1 3830 S FK506  
L2 70 S L2 AND (METHOTREXATE)  
L3 2 S L3 AND LIGAND  
L4

=> s (enzyme cleavable linker) and (dimerize protein)  
714136 ENZYME  
2512 CLEAVABLE  
12299 LINKER  
1 ENZYME CLEAVABLE LINKER  
(ENZYME(W)CLEAVABLE(W)LINKER)  
1147 DIMERIZE  
1792807 PROTEIN  
0 DIMERIZE PROTEIN  
(DIMERIZE(W)PROTEIN)  
L5 0 (ENZYME CLEAVABLE LINKER) AND (DIMERIZE PROTEIN)

=>